Data gathered: September 7
Alternative Data for Glaukos
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 27 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 92 | Sign up | Sign up | Sign up |
| Google Trends | 74 | Sign up | Sign up | Sign up |
| Patents | 61 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 262 | Sign up | Sign up | Sign up |
| Facebook Followers | 6,718 | Sign up | Sign up | Sign up |
| Instagram Followers | 2,936 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 805 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,629 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 89 | Sign up | Sign up | Sign up |
| Linkedin Employees | 867 | Sign up | Sign up | Sign up |
About Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
| Price | $129.28 |
| Target Price | Sign up |
| Volume | 608,980 |
| Market Cap | $7.05B |
| Year Range | $76.4 - $135.39 |
| Dividend Yield | 0% |
| Industry | Medical Devices |
In the news
 |
Glaukos (NYSE:GKOS) PT Raised to $145.00 at Stifel NicolausSeptember 4 - ETF Daily News |
|
Glaukos (NYSE:GKOS) Hits New 12-Month High Following Analyst UpgradeSeptember 4 - ETF Daily News |
|
Glaukos (NYSE:GKOS) Reaches New 52-Week High on Analyst UpgradeSeptember 3 - ETF Daily News |
Better Than Expected Earnings Results Boosted Glaukos Corp (GKOS) in Q2September 2 - Yahoo Entertainment |
|
Glaukos price target raised by $15 at Stifel, here's whySeptember 2 - Thefly.com |
|
|
Bank of New York Mellon Corp Buys 26,510 Shares of Glaukos Co. (NYSE:GKOS)September 1 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 96M | 89M | 73M | -51M | -24M | -0.520 |
| Q1 '24 | 81M | 88M | 65M | -41M | -31M | -0.700 |
| Q4 '23 | 81M | 91M | 63M | -37M | -25M | -0.630 |
| Q3 '23 | 75M | 73M | 60M | -30M | -21M | -0.500 |
| Q2 '23 | 77M | 73M | 60M | -33M | -23M | -0.550 |
Insider Transactions View All
| Gilliam Joseph E filed to sell 102,169 shares at $130. August 23 '24 |
| Gilliam Joseph E filed to sell 102,749 shares at $129.3. August 23 '24 |
| Stapley Marc filed to sell 34,076 shares at $126.9. August 19 '24 |
| Stapley Marc filed to sell 39,726 shares at $124. August 19 '24 |
| Stapley Marc filed to sell 38,616 shares at $125.3. August 19 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Boston ScientificBSX |
$81.6 0% | 52 |
 |
Edwards LifesciencesEW |
$66.81 0% | 40 |
 |
Intuitive SurgicalISRG |
$471.82 0% | 52 |
 |
MedtronicMDT |
$89.89 0% | 42 |
 |
StrykerSYK |
$358.92 0% | 71 |
Read more about Glaukos (GKOS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Glaukos?
The Market Cap of Glaukos is $7.05B.
What is the current stock price of Glaukos?
Currently, the price of one share of Glaukos stock is $129.28.
How can I analyze the GKOS stock price chart for investment decisions?
The GKOS stock price chart above provides a comprehensive visual representation of Glaukos' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Glaukos shares. Our platform offers an up-to-date GKOS stock price chart, along with technical data analysis and alternative data insights.
Does GKOS offer dividends to its shareholders?
As of our latest update, Glaukos (GKOS) does not offer dividends to its shareholders. Investors interested in Glaukos should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Glaukos?
Some of the similar stocks of Glaukos are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
.